Estimation of the budget impact of the dual dispensing circuit of emicizumab in France: The HemiValue study - 29/03/25
, L. Fraticelli 2, R. Ajjouri 3, G. Touvron 3, V. Chamouard 4Highlights |
• | Dispensing emicizumab in community pharmacy benefits patients and carers in terms of time and travel savings, from 26.0 h per year on average in hospital, to only 4.3 h in a community pharmacy. |
• | Patients save money; the average direct cost was €342 at hospital compared to €20 in community pharmacy. |
• | For community pharmacies, the transition to a dual dispensing circuit, with 70% of dispensations, represents an estimated revenue increase of €3.9 million. |
• | For hospital pharmacies, the transition to the dual dispensing circuit results in an estimated revenue decrease of €342,000 over all hospitals. |
• | For the overall population, the transition to a dual dispensing circuit results in a reduction of 52 tons of CO2 emissions per year. |
Abstract |
Context |
Hemophilia A is a rare bleeding disorder associated with an economic burden for patients and their caregivers. This study, called HemiValue, consists in a budget impact model to assess the benefits for patients and the budgetary impact of this shift to dual dispensing for all stakeholders involved, comparing the cost and time savings from the patients’ perspective and from the pharmacies’ perspective.
Methodology |
The impact of the dual dispensing circuit over one year was evaluated from the patients' perspective, the evaluation included costs, travel and waiting times related to obtaining the treatment, as well as associated income losses. The analysis also included perspectives from hospital pharmacies (HP), community pharmacies (CP), and ecological considerations.
Results |
On an individual level, the availability of emicizumab in CP reduced the time spent obtaining this treatment by the equivalent of 3 working days per year. The 322 euros difference in direct costs per year represents a reduction in the proportion of costs relative to the available income of families from 2.6% to 0.2%. This reduction was more pronounced for low-income households and those living more than 30 min from a HP.
Discussion |
The dual dispensing circuit reduces the financial and logistical burdens associated with obtaining emicizumab. These results highlight the importance of innovative dispensing models that aim to ease constraints for patients and their caregivers while working towards greater equity in accessibility.
Le texte complet de cet article est disponible en PDF.Keywords : Hemophilia a, Emicizumab, Community pharmacy services, Pharmacy service, Hospital economics, Pharmaceutical, Health care costs
Plan
Vol 73 - N° 2
Article 202975- avril 2025 Retour au numéro
Article précédent
- Initiative to federate research contributors: The Polyhandicap REsearch NEtwork PolyRENE
- Karine Baumstarck, Vincent Gautheron, Hugo Bessaguet, Adélaïde Brosseau-Beauvir, Sylvain Brochard, Thierry Billette de Villemeur, Mathieu Milh, Sandrine Thinnes, Anne-Emmanuelle Piquet-Massin, Marie Christine Tezenas du Montcel, Any Beltran Anzola, Sibylle Del Duca, Houria El Ouazzani, Ilyes Hamouda, Marie-Anastasie Aim, Pascal Auquier, Marie-Christine Rousseau
- One-year post-intervention effectiveness of a proportionate universal intervention in reducing social inequalities of weight status among adolescents
- Marcel Uwizeye, Mohamed Dakin, Florian Manneville, Johanne Langlois, Karine Legrand, Elisabeth Spitz, Philip Böhme, Edith Lecomte, Francis Guillemin, Serge Briançon, Abdou Omorou
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?